EFICÁCIA E LIMITAÇÕES DO ALIROCUMABE NA REDUÇÃO DE LDL-C E EVENTOS CARDIOVASCULARES - ANÁLISE EM PACIENTES COM INSUFICIÊNCIA CARDÍACA E OUTRAS CONDIÇÕES CLÍNICAS: UMA REVISÃO DE LITERATURA
EFICÁCIA E LIMITAÇÕES DO ALIROCUMABE NA REDUÇÃO DE LDL-C E EVENTOS CARDIOVASCULARES - ANÁLISE EM PACIENTES COM INSUFICIÊNCIA CARDÍACA E OUTRAS CONDIÇÕES CLÍNICAS: UMA REVISÃO DE LITERATURA
-
DOI: https://doi.org/10.22533/at.ed.65424141022
-
Palavras-chave: Alirocumabe, PCSK9, tratamento
-
Keywords: Alirocumab, PCSK9, treatment
-
Abstract: Alirocumab, a PCSK9 inhibitor, has shown efficacy in reducing LDL-cholesterol and preventing cardiovascular events in patients with atherosclerotic diseases. However, its efficacy in patients with heart failure (HF) is limited. The ODYSSEY OUTCOMES study revealed that, despite significant LDL-C reduction, alirocumab did not have a substantial impact on reducing major adverse events or HF hospitalizations. This result is consistent with other studies, such as GISSI-HF and CORONA, which also showed no significant benefits of statins in HF. The complexity of HF, with its multiple pathological mechanisms, suggests that isolated LDL-C reduction may not be sufficient to improve clinical outcomes. The efficacy of alirocumab in HF remains under investigation, and more integrated therapeutic approaches may be needed to effectively manage this condition.
- João Gabriel Costa Ferreira
- Carlos Alberto Bhering
- Iuri Duque de Souza Flor
- Pedro Aguiar Moreira
- Marcelo Almeida Novaes
